{"DataElement":{"publicId":"7055134","version":"1","preferredName":"Prostate Carcinoma Prostate Specific Antigen Measurement Disease Response Status","preferredDefinition":"The disease status or response to treatment of prostate carcinoma based on prostate specific antigen measurement.","longName":"PSAS","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"7050210","version":"1","preferredName":"Disease Response Domain Prostate Carcinoma Prostate Specific Antigen Measurement Disease Response","preferredDefinition":"A domain for disease response evaluations._One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_The determination of the prostate specific antigen present in a sample._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"6608777v1.0:7050208v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6608777","version":"1","preferredName":"Disease Response Domain","preferredDefinition":"A domain for disease response evaluations.","longName":"C107097","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response Domain","conceptCode":"C107097","definition":"A domain for disease response evaluations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6DD03A-0CB9-71AE-E053-F662850AB42C","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"ONEDATA","dateModified":"2019-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7050208","version":"1","preferredName":"Prostate Carcinoma Prostate Specific Antigen Measurement Disease Response","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:The determination of the prostate specific antigen present in a sample.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C4863:C17634:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DE2356-5A78-2B9A-E053-F662850A8403","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"ONEDATA","dateModified":"2019-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"96DE2356-5A89-2B9A-E053-F662850A8403","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"KUMMEROA","dateModified":"2020-06-18","changeDescription":"Released. AK 2020-6-10; Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3855332","version":"1","preferredName":"Prostate Specific Antigen Measurement Response Status","preferredDefinition":"The determination of the prostate specific antigen present in a sample._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"PSA_STATUS","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unconfirmed PSA PR","valueDescription":"Prostate Specific Antigen Measurement Unconfirmed Partial Remission","ValueMeaning":{"publicId":"3855333","version":"1","preferredName":"Prostate Specific Antigen Measurement Unconfirmed Partial Remission","longName":"3855333","preferredDefinition":"The determination of the prostate specific antigen present in a sample.: An operation in which a term denies or inverts the meaning of another term or construction.: Confirmed; having been established or verified.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-506F-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3ED2ABB-5088-9EF2-E040-BB89AD4342AA","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"Unconfirmed PSA CR","valueDescription":"Prostate Specific Antigen Measurement Unconfirmed Complete Remission","ValueMeaning":{"publicId":"3855334","version":"1","preferredName":"Prostate Specific Antigen Measurement Unconfirmed Complete Remission","longName":"3855334","preferredDefinition":"The determination of the prostate specific antigen present in a sample.: An operation in which a term denies or inverts the meaning of another term or construction.: Confirmed; having been established or verified.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-5097-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3ED2ABB-50B0-9EF2-E040-BB89AD4342AA","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"PSA-Progression","valueDescription":"Prostate Specific Antigen Measurement Tumor Progression","ValueMeaning":{"publicId":"3855335","version":"1","preferredName":"Prostate Specific Antigen Measurement Tumor Progression","longName":"3855335","preferredDefinition":"The determination of the prostate specific antigen present in a sample.: The molecular steps that continually advance a cancer or cancer cell into a more malignant and aggressive phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Progression","conceptCode":"C17609","definition":"A pathologic process in which alterations at the molecular level result in a more aggressive cytologic and phenotypic profile and clinical course of a neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-50BD-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3ED2ABB-50D6-9EF2-E040-BB89AD4342AA","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"PSA-NR (Borderline Stable)","valueDescription":"Prostate Specific Antigen Measurement Borderline Stable Disease","ValueMeaning":{"publicId":"3855336","version":"1","preferredName":"Prostate Specific Antigen Measurement Borderline Stable Disease","longName":"3855336","preferredDefinition":"The determination of the prostate specific antigen present in a sample.: Straddling the dividing line between two categories.: Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Borderline","conceptCode":"C14157","definition":"Straddling the dividing line between two categories.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-50E4-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3ED2ABB-50FD-9EF2-E040-BB89AD4342AA","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"PSA-Stable","valueDescription":"Prostate Specific Antigen Measurement Stable Disease","ValueMeaning":{"publicId":"3855337","version":"1","preferredName":"Prostate Specific Antigen Measurement Stable Disease","longName":"3855337","preferredDefinition":"The determination of the prostate specific antigen present in a sample.: Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-510A-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3ED2ABB-5123-9EF2-E040-BB89AD4342AA","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"PSA-PR (PR)","valueDescription":"Prostate Specific Antigen Measurement Partial Remission","ValueMeaning":{"publicId":"3855338","version":"1","preferredName":"Prostate Specific Antigen Measurement Partial Remission","longName":"3855338","preferredDefinition":"The determination of the prostate specific antigen present in a sample.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-5130-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3ED2ABB-5149-9EF2-E040-BB89AD4342AA","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"PSA-N (CR)","valueDescription":"Prostate Specific Antigen Measurement Negative Finding Complete Remission","ValueMeaning":{"publicId":"3855339","version":"1","preferredName":"Prostate Specific Antigen Measurement Negative Finding Complete Remission","longName":"3855339","preferredDefinition":"The determination of the prostate specific antigen present in a sample.: A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-5157-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3ED2ABB-5170-9EF2-E040-BB89AD4342AA","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4EF44DE-DCA3-4C6C-E040-BB89AD435952","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-27","modifiedBy":"ONEDATA","dateModified":"2013-08-27","deletedIndicator":"No"},{"value":"Not Assessed","valueDescription":"No Assessment","ValueMeaning":{"publicId":"2768467","version":"1","preferredName":"No Assessment","longName":"2768467","preferredDefinition":"The non-affirmative response to a question.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52C71733-4814-2BF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"070018CF-5B44-5049-E050-BB89AD43421B","beginDate":"2013-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"ONEDATA","dateModified":"2014-11-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3855331","version":"1","preferredName":"Prostate Specific Antigen Measurement Response Status","preferredDefinition":"The determination of the prostate specific antigen present in a sample.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C17634:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Specific Antigen Measurement","conceptCode":"C17634","definition":"The determination of the prostate specific antigen present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3ED2ABB-5026-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3ED2ABB-5037-9EF2-E040-BB89AD4342AA","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"KNABLEJ","dateModified":"2017-08-24","changeDescription":"8/24/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6921971","version":"1","longName":"CDISC Aligned Collection CDEs","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"7318366","version":"1","longName":"Response - CDISC Aligned","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"PSA status","type":"Preferred Question Text","description":"PSA status","url":null,"context":"NCI Standards"},{"name":"CDISC Aligned NCI Standard Equivalent CDE","type":"CDISC Note","description":"This data element is to be used for CDISC aligned data collection in place of CDE 3855574 from the original NCI Standard CRF Template.","url":null,"context":"NCI Standards"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"9743306F-73CF-4A7F-E053-F662850AD9B0","latestVersionIndicator":"Yes","beginDate":"2019-11-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-13","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":"Released. AK 2020-6-17; Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":"02.13.23_Set Reg Status to Standard for all CDISC Aligned content_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}